GC Cell’s immune cell therapy, Immuncell LCZ, has proven its effectiveness in long-term clinical tri..

사진 확대

[Picture = GC Cell]

GC Cell’s immune cell therapy, Immuncell LCZ, has proven its effectiveness in long-term clinical trials for nine years. The survival period without recurrence was extended by 14 months compared to the control group, and the risk of cancer-related death was reduced by 51%.

GC Cell announced on the 30th that the results of a long-term clinical study on hepatocellular carcinoma patients of immunocyte therapy ImmuncellLC were published in an international journal.

The study integrated and analyzed the results of long-term follow-up of Phase 3 randomized controlled clinical trials (RCT) subjects for about 9 years and large-scale real-world clinical data obtained in real-world medical settings. The long-term clinical efficacy of ImmuncellLC was verified in patients with hepatocellular carcinoma with high recurrence rates even after radical treatment.

According to the results, the immunotherapy group administered ImmuncellLC was extended by 14 months from the median survival time without recurrence (mRFS) compared to the control group, and the risk of recurrence decreased by 28%. In the overall survival (OS) analysis, the immunotherapy group showed a tendency to reduce the risk of death compared to the control group. Cancer-specific survival rates (CSS) improved significantly in the immunotherapy group, reducing the risk of cancer-related death by 51%.

In addition, a long-term follow-up analysis based on actual clinical data from two advanced medical institutions in Korea also showed that the median survival time without recurrence was extended by 35.5 months compared to the control group, and the risk of recurrence decreased by 36%.

The company said, “The data evaluating survival effects over such a long period of time in the field of immune cell therapy are very rare, so it is evaluated as a result of clearly showing the long-term clinical value of liver cancer-assisted immunotherapy.”

“After nine years of long-term follow-up and analysis of actual clinical data (RWD) after demonstrating safety and effectiveness through phase 3 clinical trials for liver cancer, we have confirmed strong evidence that immune cell therapy has clinical utility as a continuous adjuvant immune treatment strategy for liver cancer,” said Junghoon Lee, a professor of gastroenterology at Seoul National University Hospital who led the study. “The value of Immune Cell LC, which can reduce recurrence of liver cancer for a long time, is even greater at a time when even large-scale multi-national clinical trials to reduce recurrence of liver cancer using immuno-cancer drugs have recently failed.”

Won Sung-yong, CEO of GC Cell, said, “It is very meaningful that this long-term follow-up clinical result was officially announced through the paper,” adding, “Based on the clinical evidence accumulated in the domestic market, we expect it to be a reliable treatment option for liver cancer patients and medical staff.” In addition, based on this achievement, we will do our best to advance overseas in the future,” he said.